STUDY OF INFLUENCE OF BIOPREPARATE «MICROFIT» FOR THE CONDITION INTERNAL ORGANS OF LABORATORY RATS
Main Article Content
Authors
K.D. Zakarya
Republic Collection of Microorganisms, Valikhanov street, 13/1, Astana, 010000, Kazakhstan
Z.S Sarmurzina
Republic Collection of Microorganisms, Valikhanov street, 13/1, Astana, 010000, Kazakhstan
R.T. Dospaeva
Republic Collection of Microorganisms, Valikhanov street, 13/1, Astana, 010000, Kazakhstan
G.N. Bissenova
Republic Collection of Microorganisms, Valikhanov street, 13/1, Astana, 010000, Kazakhstan
Z.T. Shulgau
National Center for Biotechnology, 13/5, Korgalzhyn road, Astana, 010000, Kazakhstan
A.E. Gulyaev
National Center for Biotechnology, 13/5, Korgalzhyn road, Astana, 010000, Kazakhstan
T.N. Krivoruchko
National Center for Biotechnology, 13/5, Korgalzhyn road, Astana, 010000, Kazakhstan
B.B. Zhetpisbaev
National Center of Neurosurgery, Avenue Turan, 34/1, Astana, 010000, Kazakhstan
Abstract
The article describes experimental results of preclinical tests of the combined biopreparation “Microfit” intended for prevention and correction of intestinal microflora. The preparation consists of lactic acid bacteria of the genus Lactobacillus, an extract of balsamic poplar and tagansorbent. Pre-clinical study of the safety of the biopreparation “Microfit” on the state of internal (absolute and relative mass) organs of laboratory animals was conducted. According to the results, it was established that the biopreparation “Microfit” with the course of intragastric rat administration to rats at the conventional therapeutic dose (30 mg/kg) and the dose 10 times higher than the conventional therapeutic dose (300 mg/kg) had not led to a general toxic and destructive effect on the internal organs of animals. The safety of the biopreparation “Microfit” after intragastric administration and good tolerance of animals was confirmed. The results allow approving safety of the tested biological product.
Keywords
research, biopreparation, toxicity, conditional therapeutic dose, laboratory animals, internal organs
Article Details
References
SorokulovaI. Preclinical Testing in the Development of Probiotics: A Regulatory Perspective with Bacillus Strains as an Example. Clinical Infectious Diseases., 2008, vol. 46 (2), рр.92-95.
HayesC.L., NatividadJ.M., Jury J., MartinR.,LangellaP., VerduE.F. Efficacy of Bifidobacterium breveNCC2950 against DSS-induced colitis is dependent on bacterial preparation and timing of administration.J Beneficial Microbes, 2014, vol. 5 (1), рр.79-88.
Sylvie R., Mathilde J., Valérie D., Laurent N. Impact of the gut microbiota on the neuroendocrine and behavioural responses to stress in rodents. Оcl-oilseeds and fats crops and lipids., 2016, vol. 23(1).D116, рр.1-7.
Mark S.G., Ross N.B., Philip M.G., Gordon S.H. Lactobacillus fermentum BR11, a potential new probiotic, alleviates symptoms of colitis induced by dextran sulfate sodium (DSS) in rats.International Journal of Food Microbiology, 2007, vol.114(3), рр. 267-274.
№442-2007. Pravila provedenija doklinicheskih issledovanij, mediko-biologicheskih jeksperimentov iklinicheskihis pytanij v Respublike Kazahstan [Rules for preclinical research, medical and biological experiments and clinical trials in the Republic of Kazakhstan].
Mironov A.N. Rukovodstvo po provedeniju doklinicheskih issledovanij lekarstvennyh sredstv.Chast' pervaja [A guide to preclinical drug research.Part one]. Moscow, 2012, 944 p.
Habrieva R.U. Rukovodstvo po jeksperimental'nomu (doklinicheskomu) izucheniju novyh farmakologicheskih veshhestv[Manual on experimental (preclinical) study of new pharmacological substances].Moscow, 2005, 832 p.
ST RK 1613-2006. Nadlezhashhaja laboratornaja praktika [ST RK 1613-2006. Good Laboratory Practice].Introduced 2008.